1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Vital Signs - Lowering Drug Development Costs with Genetically Modified Swine 

Lowering Drug Development Costs with Genetically Modified Swine

The US pharmaceutical industry spends approximately $ billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately years and over $ billion to bring to market.
Then, only one in every to drugs is approved by the Food and Drug Administration (FDA). On average, pre-clinical testing for one drug candidate alone costs $ to $ million. These high costs and long drug development intervals are due, in part, to the use of animal models that are not predictive of how the drugs will perform during subsequent human clinical trials. The use of genetically-modified swine for pre-clinical efficacy and toxicity studies will improve the predictive nature of pre-clinical testing and inevitably lower drug and medical device development costs. As a result, patients will receive needed medications faster and more affordably.

Pre-clinical tests involve translational research in which medical devices and/or pharmaceutical products are tested on animals. In these studies, animals are used that express symptoms similar to those found in humans and the results are extrapolated to predict the probability of success when tested in humans. Yet, the predictive ability of animal trials is limited. In many cases, the animals do not have the exact same diseases as those found in humans, but instead are induced to express physiological symptoms similar to those found in humans.

Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states and their physiological responses to treatment. Swine have been increasingly used as the animal model of choice because their anatomy, genetics, and physiology are more similar to humans than traditional animal models such as mice (Bendixen et al., 2010).

Table Of Contents

Vital Signs - Lowering Drug Development Costs with Genetically Modified Swine 
1VITAL SIGNS - LOWERING DRUG DEVELOPMENT COSTS WITH GENETICALLY MODIFIED SWINE

Vital Signs - February 2016
1 February 2016 Issue

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.